Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19 + B cell tumors: a phase 1/2 trial.

MLA

Marin, David, et al. “Safety, Efficacy and Determinants of Response of Allogeneic CD19-Specific CAR-NK Cells in CD19 + B Cell Tumors: A Phase 1/2 Trial.” Nature Medicine, vol. 30, no. 3, Mar. 2024, pp. 772–84. EBSCOhost, https://doi.org/10.1038/s41591-023-02785-8.

APA

Marin, D., Li, Y., Basar, R., Rafei, H., Daher, M., Dou, J., Mohanty, V., Dede, M., Nieto, Y., Uprety, N., Acharya, S., Liu, E., Wilson, J., Banerjee, P., Macapinlac, H. A., Ganesh, C., Thall, P. F., Bassett, R., Ammari, M., … Rezvani, K. (2024). Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19 + B cell tumors: a phase 1/2 trial. Nature Medicine, 30(3), 772–784. https://doi.org/10.1038/s41591-023-02785-8

Chicago

Marin, David, Ye Li, Rafet Basar, Hind Rafei, May Daher, Jinzhuang Dou, Vakul Mohanty, et al. 2024. “Safety, Efficacy and Determinants of Response of Allogeneic CD19-Specific CAR-NK Cells in CD19 + B Cell Tumors: A Phase 1/2 Trial.” Nature Medicine 30 (3): 772–84. doi:10.1038/s41591-023-02785-8.